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Introduction
Chronic myeloproliferative hemopathies (CMPH) as a whole are the most
common chronic leukemias in the elderlies in the structure of morbidity by
hematological malignancies with primary bone marrow involvement, being
characterized in the advanced stages by recurrent evolution and negative
socio-economic impact.
Purpose: Diagnosis identification and evaluation of management of CMPH.
Material and methods
A clinico-analytical, descriptive, study was realized along with the narrative
review of the international literature on the subject. The study enrolled 91
elderly patients with different phases of chronic myeloid leukemia (CML),
primary myelofibrosis (PMF) and polycythemia vera (PV), who were followed
up and treated at the PMSI Institute of Oncology in the period of 1995 – 2020.
The following research methods were used: epidemiological, decsriptive,
comparative, clinical-analytical, and cohort statistics. More than 50 reference
bibliographic sources have been studied. According to the impact score, 25
relevant primary sources were identified and selected with a scientific,
reproducible and transparent approach.
84.6%), constituting 25 (80.6%) cases in PV, and 25 (73.5%) cases in PMF. The
duration of the disease from the time of onset of the initial clinical symptoms to
diagnosis ranged in PMF between 1.4-7 months (median – 3.7±0.63 months), in
CML between 1.5-12 months (median – 2.1±0.37 months) and in PV between 1-7
months (median – 3.8±0.54 months). Under the combination of chemotherapy and
phlebotomies the clinico-hematological remission was achieved in all 31 patients
with PV. The duration of response ranged from 3 to 9 months (median – 5.8
months). In all cases, the disease relapsed, with plethoric syndrome and
thrombocytosis, which required the resumption of induction chemotherapy with
busulfan, hydroxycarbamide, with regaining remissions. In elderly patients the
overall survival over one year constituted 100%, over 5 years – 93.5%, over 10
years – 76.4% , being lower than those registered in all patients with PV (over one
year – 100%, 5 years – 98.6%, 10 years – 85.9%).
Conclusions
The long-term results of treatment in elderly patients with CMPH fail to those in the
CMPH totality because of the development of age-related diseases and vascular
accidents on the account of leuko-, thrombocytosis. The targeted treatment with
TKIs remains a curative option of choice for CML patients of 60 years and more. In
the elderly PV patients no significant difference was revealed in short- and long-
term outcomes of chemotherapy with busulfan and hydroxycarbamide in
combination with phlebotomy, being totally superior to those in PMF patients. The
review of the literature shows that the patients with CMPH, especially those elderly,
may endure a sizeable unfavorable impact on their employment status, which in
turn may be associated with the reduced annual household income.























Figura 1. Five-year survival  of elderly patients with CMPH
Results
Thirty-four (37.3%) patients with PMF, 26 (28.6%) – with CML and 31 (34.1%) –
with PV were diagnosed in the elderly age groups and followed up by our
study. The age group of 60-69 years was more numerous in CML (22 cases, or
84.6%), constituting 25 (80.6%) cases in PV, and 25 (73.5%) cases in PMF.
Tabel 1. Disease span until diagnosis in CMPH
Thirty-four (37.3%) patients with PMF, 26 (28.6%) – with CML and 31 (34.1%) –
with PV were diagnosed in the elderly age groups and followed up by our
study. The age group of 60-69 years was more numerous in CML (22 cases, or
Type of CMPH
Range of the disease span until 
diagnosis, month
Median of the disease span until 
diagnosis, months
CML 1.5-12 2.1±0.37
PMF 1.4-7 3.7±0.63
PV 1-7 3.8±0.54
